Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | NPY1R | P25929 | 11/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 2/20 | 0.32 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9674013 | 0.78 | CXCR4 (0.49) | NAAAHRH3HRH4NPY1RSLC6A2 | |
| SCHEMBL9676455 | 0.76 | CXCR4 (0.48) | NAAAHRH3HRH4NPY1RSLC6A2 | |
| SCHEMBL9673755 | 0.76 | CXCR4 (0.48) | NAAAHRH3HRH4NPY1RSLC6A2 | |
| SCHEMBL4378119 | 0.76 | CXCR4 (0.41) | NAAAHRH3HRH4NPY1RSLC6A2 | |
| SCHEMBL9668263 | 0.73 | NAAA (0.45) | NAAAHRH3HRH4NPY1RSLC6A2 | |
| SCHEMBL7704486 | 0.73 | HRH3 (0.53) | NAAAHRH3HRH4SLC6A2SLC6A4 | |
| SCHEMBL5488178 | 0.72 | HRH3 (0.45) | NAAAHRH3HRH4NPY1RCXCR4 | |
| SCHEMBL4666468 | 0.72 | CXCR4 (0.40) | NAAAHRH3HRH4NPY1RSLC6A2 | |
| SCHEMBL11170648 | 0.71 | HRH3 (0.51) | NAAAHRH3HRH4NPY1RSLC6A2 | |
| SCHEMBL3816667 | 0.71 | SLC6A2 (0.42) | NAAAHRH3HRH4NPY1RSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030199491-A1 | Quinoline derivatives having vegf inhibiting activity | ASTRAZENECA AB (SE) | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199491-A1 | Quinoline derivatives having vegf inhibiting activity | VEGFA, FLT1, FLT4 | NAAA 4802/4885HRH3 145/4885HRH4 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.